The influence of family history on prostate cancer risk: Implications for clinical management

BJU International

Volumn 107, Issue 5, 2011, Pages 716-721

  Madersbacher, Stephan ^a   Alcaraz, Antonio ^b   Emberton, Mark ^c   Hammerer, Peter ^d   Ponholzer, Anton ^e   Schröder, Fritz H ^f   Tubaro, Andrea ^g  

^a DANUBE HOSPITAL   (Austria)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d Academic Hospital   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

chemoprevention; family history; hereditary; prostate cancer; risk factor; screening

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; DUTASTERIDE; FINASTERIDE; PLACEBO;

AGE DISTRIBUTION; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CLINICAL ASSESSMENT; DATA BASE; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC ASSOCIATION; HAZARD RATIO; HEALTH PROFESSIONALS FOLLOW UP STUDY QUESTIONNAIRE; HIGH RISK POPULATION; HUMAN; ONSET AGE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUESTIONNAIRE; RELATIVE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN SUPPLEMENTATION;

5-ALPHA REDUCTASE INHIBITORS; ADULT; AGED; EARLY DETECTION OF CANCER; FAMILY HEALTH; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 79952273198     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10024.x     Document Type: Review

References (21)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
2. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
3. Roobol MJ, Schroder FH, Crawford ED, et al. A framework for the identification of men at increased risk for prostate cancer. J Urol 2009; 182: 2112-20
4. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P,. Relative risk of prostate canc (Pubitemid 37339734)
5. Schleutker J, Matikainen M, Smith J, et al. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease. Clin Cancer Res 2000; 6: 4810-5 (Pubitemid 32110424)
6. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85 (Pubitemid 30451850)
7. Christensen GB, Baffoe-Bonnie AB, George A, et al. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. Prostate 2010; 70: 735-44
8. Sun J, Kader AK, Hsu FC, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate 2010; [Epub ahead of print]. DOI: 10.1002/pros.21256
9. Xu J, Zheng SL, Isaacs SD, et al. Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci USA 2010; 107: 2136-40
10. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802 (Pubitemid 23241269)
11. Johns LE, Houlston RS,. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003; 91: 789-94 (Pubitemid 36724060)
12. Bratt O,. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906-13
13. Chen YC, Page JH, Chen R, Giovannucci E,. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008; 68: 1582-91
14. Brandt A, Bermejo JL, Sundquist J, Hemminki K,. Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. Eur Urol 2010; 58: 275-80
15. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D,. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008; 123: 1154-9
16. Norrish AE, McRae CU, Cohen RJ, Jackson RT,. A population-based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 1999; 84: 311-5 (Pubitemid 29376180)
17. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24 (Pubitemid 36859473)
18. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34 (Pubitemid 43898816)
19. National Comprehensive Cancer Network. Prostate Cancer Early Detection, V.2.2010; 2010. Available at:. Accessed November 2010
20. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
21. Tammela TL, Andriole GL, Teloken C, Wilson TH, Fowler IL,. The influence of a positive family history on prostate cancer incidence and dutasteride efficacy in the REDUCE study. Eur Urol Suppl 2010; 9: 301 (abstract 960)